China has completed the monitoring information system for adverse drug reactions

From the official website of the State Administration of Food and Drug Administration was informed that on October 15, the 37th Annual Meeting of the World Health Organization's International Drug Monitoring Cooperation Program member countries was held in Tianjin, which is also the first time since China joined the International Drug Monitoring Cooperation Program in 1998, the first time to host this annual meeting. Wu Wei, deputy director of the State Administration of Food and Drug Administration, pointed out at the meeting that China has now established three-level monitoring institutions at the national, provincial and municipal levels to complete the monitoring information system for adverse reactions.
drug monitoring and safety monitoring of the entire life cycle of drugs, from drug development to drug production, marketing and use, are indispensable scientific means to ensure drug safety. In recent years, with the rapid development of the pharmaceutical industry, China's drug regulatory capacity is increasing, laws and regulations are constantly improving, technical standards are basically in line with international standards, drug safety monitoring has been more and more strengthened.
Wu pointed out that since joining the International Drug Monitoring Cooperation Program in 1998, China's drug adverse reaction monitoring and evaluation has developed rapidly and exchanges and cooperation with WHO and countries have become increasingly close. In order to do a good job in monitoring adverse drug reactions, China has now established three-level monitoring institutions at the national, provincial and municipal levels, with nearly 400 monitoring institutions at all levels across the country jointly assuming responsibility for the monitoring and management of adverse reactions; (NetEase News)